Chow AK, Daniel EE, Schulz R. Cardiac function is not significantly diminished in hearts isolated from young caveolin-1 knockout mice. Am J Physiol Heart Circ Physiol 299: H1183-H1189, 2010. First published August 6, 2010; doi:10.1152/ajpheart.01195.2009 are known to degrade components of the extracellular matrix. More recently, in myocardial oxidative stress injury including ischemia-reperfusion, MMP-2 is activated and degrades troponin I and ␣-actinin. MMP activity is regulated at several levels. We recently showed that MMP-2 is localized in the caveolae of cardiomyocytes and is negatively regulated by caveolin-1 (Cav-1). The caveolin scaffolding domain of Cav-1 inhibits MMP-2 proteolytic activity in vitro, and Cav-1 Ϫ/Ϫ mouse hearts have increased MMP-2 activity compared with controls. Whether this increase in MMP-2 activity translates to impaired cardiac function is unknown. Hearts isolated from Cav-1 Ϫ/Ϫ mice and their wild-type controls were perfused as isolated working hearts and physiologically challenged with increasing increments of left atrial preload (7-22.5 mmHg). The hearts were then pharmacologically challenged with increasing concentrations of isoproterenol (0.1-100 nM). Functionally, the Cav-1 Ϫ/Ϫ hearts were similar to the controls in heart rate, peak systolic pressure, developed pressure, and rate pressure product. At higher preload pressures, the Cav-1 Ϫ/Ϫ hearts outperformed the control hearts. Coronary flow was significantly higher in Cav-1 Ϫ/Ϫ hearts under all conditions. The highest concentration of isoproternol increased the heart rate of Cav-1 Ϫ/Ϫ hearts more than in controls. Western blot analysis revealed no significant changes in troponin I or ␣-actinin between Cav-1 Ϫ/Ϫ hearts and their controls. There was a significant loss of MMP-2 from both knockout and control hearts during the perfusion. In summary, despite the loss of Cav-1, Cav-1 Ϫ/Ϫ hearts show similar or better cardiac function compared with wild-type hearts following physiological challenge or ␤-adrenergic stimulation in vitro, and this appears unrelated to changes in MMP-2. isolated hearts; matrix metalloproteinase-2 MATRIX METALLOPROTEINASES (MMPs) are a large family of zinc-dependent endopeptidases best known for their proteolysis of extracellular matrix proteins to effect remodeling of tissues in both physiological and pathological processes. MMPs have recently been shown to play a role in targeting non-matrix proteins such as cytokines and cell surface receptors (12, 23). In contrast, MMP-2 has been shown to have biological actions within cardiac myocytes where it degrades susceptible sarcomeric and cytoskeletal proteins such as troponin I (27), myosin light chain-1 (22), and ␣-actinin (26) under conditions of enhanced oxidative stress.
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Because of the significant physiological and pathological actions of MMPs, it is essential that MMP activation and activity is tightly regulated. MMPs can be activated in a number of ways. MMPs are produced in a full-length zymogen form, and the proteolytic removal of the NH 2 -terminal propeptide domain results in a truncated and active MMP. Alternatively, full-length MMP can also be activated by peroxynitrite, which oxidizes a cysteine residue in the propeptide domain that is coordinated with the catalytic zinc ion (15, 16) . We have also recently shown that MMP-2 is a phosphoprotein, and its activity can be regulated via phosphorylation (20) .
The study of the regulation of extracellular MMP activity has traditionally centered on the examination of the tissue inhibitors of metalloproteinases, of which there are four (14) . The role of the tissue inhibitors of metalloproteinases in regulating MMP activity has been explored almost exclusively in the extracellular milieu, and little is known about the regulation of intracellular MMPs.
One candidate protein that may be involved in the regulation of intracellular MMP activity is caveolin-1 (Cav-1). The caveolin family of proteins is made up of three integral membrane proteins that are found embedded in the inner leaflet of the plasma membrane. Cav-1 is the best characterized of the three and contains a domain known as the caveolin scaffolding domain, which has been demonstrated to be responsible for the binding and inhibition of a number of intracellular proteins, including endothelial nitric oxide (NO) synthase (9) . MMP-2 has been shown to localize to the caveolae of both endothelial cells (18) and cardiomyocytes (4, 5) , and evidence suggests that Cav-1 may play a role in the regulation of this enzyme. We showed that Cav-1 knockout mouse hearts have increased MMP-2 activity. MMP-2 proteolysis of an internally quenched, artificial fluorogenic substrate is inhibited by the caveolin scaffolding domain (5) . Whether the increased MMP-2 activity found in Cav-1 knockout hearts affects cardiac function, whether by physiological or pharmacological challenges, is currently unknown.
In this study, we used an isolated working mouse heart model to elucidate whether increased MMP-2 activity found in Cav-1 Ϫ/Ϫ hearts affects cardiac function during physiological or pharmacological challenges. We used Cav-1 Ϫ/Ϫ hearts at an age (6 -8 wk old) where they show no obvious signs of pathology since older Cav-1 Ϫ/Ϫ mice show signs of cardiac hypertrophy and structural changes (13, 29) .
MATERIALS AND METHODS
Protocols were approved by the University of Alberta Animal Policy and Welfare Committee, and experiments were performed in accordance with the Canadian Council on Animal Care Guide to the Care and Use of Experimental Animals.
Animals. Male 6-to 8-wk-old Cav-1 Ϫ/Ϫ (cav Ͻ tm 1 M Is Ͼ /J) and control [(B6 129 SF2/J) (Cav-1 ϩ/ϩ )] mice were obtained from Jackson Laboratories (Bar Harbor, ME).
Isolated working mouse heart. Mice were injected with heparin (100 IU ip) 10 min before euthanasia by intraperitoneal pentobarbital sodium injection. Hearts were rapidly excised from deeply anesthetized mice and placed immediately into an ice-cold Krebs-Henseleit bicarbonate solution containing (in mM) 118 NaCl, 25 NaHCO 3, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2.25 CaCl2, 0.5 EDTA, and 11.1 glucose, oxygenated with 95% O2-5% CO2 (pH 7.4). The aorta was then cannulated with a 20-gauge cannula and perfused in Langendorff mode at 60 mmHg constant hydrostatic pressure at 37°C with the aforementioned Krebs-Henseleit solution. The left atrium was then cannulated through the pulmonary opening, and the heart is switched from the Langendorff mode to the working mode whereby the heart is perfused with a recirculating Krebs-Henseleit bicarbonate solution (total volume, 125 ml) at 37°C, supplemented with 0.2% bovine serum albumin, 5 mM pyruvate, and 100 mU/l human insulin and continuously gassed with 95% O 2-5% CO2 (pH 7.4) at a left atrial preload pressure of 11.5 mmHg and an aortic afterload pressure of 50 mmHg. Spontaneously beating hearts were allowed to equilibrate aerobically for 30 min. Following this, the hearts were physiologically challenged by a stepwise adjustment of the preload pressure to 7, 10, 15, 20, and 22.5 mmHg for 2 min at each pressure. The preload was then returned to 11.5 mmHg for 20 min to allow hearts to recover from the preload challenge. The hearts were then pharmacologically challenged by a sequential administration of 0.1, 1, 10, and 100 nM dl-isoproterenol (Calbiochem) for 2 min at each concentration. Functional measurements were continuously recorded with the MP100 system from AcqKnowledge (BioPac Systems, Santa Barbara, CA) for a total of 90 min. Cardiac output was measured via a Doppler flow probe (Transonic Systems, Ithaca, NY) placed in the left atrial line, whereas aortic flow was measured using a probe in the aortic afterload line. Heart rate and peak systolic and developed (systolic Ϫ diastolic) pressures were measured with a pressure transducer (Harvard Apparatus, South Natick, MA), placed at the level of the heart, in the aortic line. Cardiac work was calculated as the product of peak systolic pressure and cardiac output. Coronary flow was calculated as the difference between cardiac output and aortic flows. The rate pressure product is the product of the heart rate and the peak systolic pressure. At the end of the perfusion, whole hearts were then clamped with Wollenberger tongs precooled in liquid nitrogen and stored at Ϫ80°C until used.
Langendorff mouse hearts. To control for the effects of in vitro heart perfusion, the hearts were isolated from an additional series of heparin-treated mice as above and perfused with a nonrecirculating Krebs-Henseleit solution only in Langendorff mode at 60 mmHg constant hydrostatic pressure for 10 or 90 min at 37°C with the aforementioned Krebs-Henseleit bicarbonate solution and frozen as above.
Tissue preparation. Frozen whole heart tissues were crushed and powdered in liquid nitrogen and weighed. Four volumes (wt/vol) of ice-cold homogenization buffer (pH 7.4), containing 50 mM Tris, 31 mM sucrose, 1 mM dl-dithiothreitol, 0.1% Triton X-100, 10 g/l soybean trypsin inhibitor, 10 mg/l leupeptin, 2 g/l aprotinin, and 100 mg/l phenylmethylsulfonyl fluoride, was added to the tissue. The powdered tissues were then homogenized with a Polytron, 3 ϫ 30 s with 30 s of cooling in ice between each cycle. The samples were then centrifuged (4°C, 1,000 g, 5 min), and the ϩ/ϩ (OE) (N ϭ 9) and Cav-1 Ϫ/Ϫ () (N ϭ 6) with varying preload pressures. *P Ͻ 0.05 within group differences. †P Ͻ 0.05 between group differences. P values are listed where interaction effects of preload and strain effects are significant. Error bars indicate means Ϯ SE where they exceed the symbol size. bpm, Beats/min. supernatants were used for the determination of enzyme activities and Western blot analysis. Protein concentration was assessed by the bicinchoninic acid method using bovine serum albumin as a reference standard.
Western blot analysis. Forty micrograms protein of each whole heart sample were run in 10% SDS-PAGE under reducing conditions. Human recombinant MMP-2 and troponin I were loaded as controls. Following electrophoresis, samples were electroblotted onto polyvinylidene difluoride membranes. The membranes were then blocked at room temperature for 1 h with 5% milk, followed by an overnight incubation at 4°C with primary antibodies [1:1,000 monoclonal mouse anti-human troponin I (Novogen), 1:1,000 monoclonal mouse anti human ␣-actinin (Chemicon), 1:1,000 monoclonal mouse anti-human MMP-2 (Chemicon)]. These membranes were then probed with 1:5,000 anti-mouse horseradish peroxidase-conjugated secondary antibody and incubated with enhanced chemiluminescence (ECL) or ECL Plus (Amersham) for 5 min before being exposed to film. Membranes were Ponceau stained to ensure equal loading (21) .
Gelatin zymography. Forty micrograms protein of each sample were run in an 8% polyacrylamide gel containing 2 mg/ml gelatin. Conditioned media from HT-1080 human fibrosarcoma cells was used as a standard for MMP-2 activity. Following electrophoresis, the gel was washed 3 ϫ 20 min in 2.5% Triton X-100. The gel was then incubated in 50 mM Tris·HCl, 150 mM NaCl, and 5 mM CaCl 2 (pH. 7.6) for 30 h at 37°C before being stained with 0.05% Coomassie brilliant blue in 25% methanol:10% acetic acid for 1 h and destained with 4% methanol:8% acetic acid for 30 min.
Data analysis. Western blots and zymograms were analyzed using ImageJ software (National Institutes of Health). Statistics and graphs were compiled using GraphPad Prism 4.03.
Statistics. Data are expressed as means Ϯ SE. The functional differences between groups were analyzed by two-way repeatedmeasures analysis of variance and, if significant, followed by Bonferroni post hoc tests. Differences in protein levels were analyzed using Student's t-test. Gelatinolytic activity was measured by Student's t-test or two-way analysis of variance, as appropriate. P values of Ͻ0.05 were considered statistically significant.
RESULTS
Response of Cav-1 knockout mouse hearts to preload challenge. Following the equilibration period, there were no differences between Cav-1 Ϫ/Ϫ (N ϭ 6) and Cav-1 ϩ/ϩ (N ϭ 9) mouse hearts in any of the measured or calculated functional parameters (heart rate, cardiac output, aortic flow, cardiac work, coronary flow, developed pressure, peak systolic pressure, and rate pressure product) (data not shown). During the preload challenge, the Cav-1 ϩ/ϩ and Cav-1 Ϫ/Ϫ mouse hearts did not significantly differ from each other at 7, 10, or 15 mmHg (Fig. 1) . At preload pressures of 15, 20, and 22.5 mmHg, Cav-1 Ϫ/Ϫ hearts demonstrated a significantly increased coronary flow when compared with Cav-1 ϩ/ϩ hearts (P Ͻ 0.05 at 15 mmHg, P Ͻ 0.01 at 20 mmHg, and P Ͻ 0.001 at 22.5 mmHg) (Fig. 1) . Also, at 20 and 22.5 mmHg of left atrial preload pressure, Cav-1 Ϫ/Ϫ hearts demonstrated an increased cardiac output when compared with controls (P Ͻ 0.05 at 20 mmHg, and P Ͻ 0.001 at 22.5 mmHg). Consequently, cardiac work is also increased at these pressures in Cav-1 Ϫ/Ϫ hearts (P Ͻ 0.05 at 20 mmHg, and P Ͻ 0.01 at 22.5 mmHg). The interaction effects of preload and strain were observed in cardiac output (P ϭ 0.001), cardiac work (P ϭ 0.0034), heart rate (P ϭ 0.0373), and coronary flow (P Ͻ 0.0001) (Fig. 1) measures. No differences were observed in aortic flow, peak systolic pressure, developed pressure, or rate pressure product measures.
Response of Cav-1 knockout mouse hearts to isoproterenol challenge. Administration of isoproterenol caused a concentration-dependent increase in heart rate and developed pressure and, consequently, rate pressure product in the hearts from both strains of mice (Fig. 2 ). An interaction effect of isoproterenol concentration and mouse strain was observed in heart rate (P ϭ 0.0389), aortic flow (P ϭ 0.0156), and rate pressure product (P ϭ 0.0458) measures. Isoproterenol (100 nM) resulted in a significantly higher heart rate (P Ͻ 0.05) and rate pressure product (P Ͻ 0.05) in Cav-1 Ϫ/Ϫ hearts compared with controls. Coronary flow was increased in Cav-1 Ϫ/Ϫ hearts at all concentrations of isoproterenol (P Ͻ 0.05) (Fig. 2) .
MMP-2 activity and protein content in Cav-1 Ϫ/Ϫ mouse hearts following preload and adrenergic challenges. Gelatin zymography did not reveal any differences in MMP-2 activity between Cav-1 ϩ/ϩ and Cav-1 Ϫ/Ϫ mouse hearts (Fig. 3A) . Additionally, MMP-2 protein content is not different between the Cav-1 ϩ/ϩ and Cav-1 Ϫ/Ϫ hearts (Fig. 3B) . Figure 3C illustrates the amount of MMP-2 activity per unit of MMP-2 protein.
Sarcomeric and cytoskeletal protein levels in Cav-1 Ϫ/Ϫ mouse hearts following preload and isoproterenol challenges. An examination of the levels of sarcomeric and cytoskeletal proteins known to be proteolyzed by MMP-2 in the Cav-1 ϩ/ϩ and Cav-1 Ϫ/Ϫ hearts did not reveal any differences between the two strains. No differences in the levels of troponin I (Fig. 4A) or ␣-actinin (Fig. 4B) were apparent in the hearts from either Cav-1 ϩ/ϩ or Cav-1 Ϫ/Ϫ mice.
MMP-2 activity in Cav-1
Ϫ/Ϫ mouse hearts Langendorff perfused for 10 or 90 min. Previously, we noted significantly greater MMP-2 activity in Cav-1 Ϫ/Ϫ hearts perfused briefly (10 min in Langendorff mode) (5) compared with this study where hearts were perfused for 90 min as isolated working hearts. To determine whether the duration of perfusion affected MMP-2 activity, Cav-1 Ϫ/Ϫ and Cav-1 ϩ/ϩ hearts were perfused for 10 or 90 min in Langendorff mode and then snap frozen for a determination of myocardial MMP-2 activity. The 72-kDa gelatinolytic activity of both the Cav-1 ϩ/ϩ and Cav-1
mouse hearts is significantly greater in hearts that were perfused for 10 min when compared with hearts perfused for 90 min (P Ͻ 0.0001) (Fig. 5) . Cav-1 Ϫ/Ϫ hearts also demonstrate higher gelatinolytic activity when compared with Cav-1 ϩ/ϩ hearts after 10 min of perfusion (P ϭ 0.0332).
DISCUSSION
The purpose of this study was to evaluate whether the Cav-1 Ϫ/Ϫ mouse hearts, which have previously been shown to have higher basal levels of MMP-2 activity (5), are functionally different from their wild-type controls when exposed to stimuli similar to what may be experienced physiologically. Interestingly, following the physiological and pharmacological challenges, no difference in MMP-2 activity was observed between Cav-1 ϩ/ϩ and Cav-1
hearts (90 min total perfusion time). This is in contrast to hearts that were perfused for 10 min before freezing, where Cav-1
hearts show significantly increased MMP-2 activity (5) (Fig. 5) . As a result of the challenges and/or longer perfusion times in this study, the MMP-2 in hearts may have been released into the perfusate, consistent with the observation that myocardial MMP-2 activity is lost over an extended perfusion time because of the mild oxidative stress inherent in isolated heart perfusions (28).
Perhaps as a result of the differential losses of MMP-2, Cav-1
mouse hearts fared better during preload challenges than Cav-1
hearts. This may also be the result of the reduced membrane binding of MMP-2 by Cav-1 in Cav-1 Ϫ/Ϫ hearts. As a result, MMP-2 would be more readily removed from the heart during perfusion and thus would not have the opportunity to cause damage. The improved function of the Cav-1 Ϫ/Ϫ hearts during the preload challenge is particularly evident in the coronary flow measurements. We hypothesize that as a result of the absence of Cav-1, endothelial NO synthase activity might be increased (3) and thus results in vasodilatation, which is reflected as an increased cardiac output and consequently cardiac work. Echocardiographic data obtained by other groups demonstrate a lack of functional difference between Cav-1 Ϫ/Ϫ and Cav-1 ϩ/ϩ hearts from 8 -10-wk-old mice (17) , though these mice were not exposed to changing preloads or adrenergic stimulation.
The ␤-adrenergic receptor has been previously found to be localized to caveolae in the cardiac myocyte (19) and colocalized with Cav-3 (11) . It has been proposed that caveolin is responsible for scaffolding the components of the ␤-adrenergic signaling cascade (24) , which would result in a rapid and effective conveyance of signal propagation. Thus we hypothesized that this signal transduction would be perturbed in hearts that lack Cav-1. The lack of difference between Cav-1 Ϫ/Ϫ and Cav-1 ϩ/ϩ heart function in response to an adrenergic agonist was unexpected, given that Cav-1 Ϫ/Ϫ mice have altered adrenergic receptor function in the gut (7) . This altered function in the gut did not appear to reflect altered ␤-adrenergic receptor location but was likely a result of perturbed protein kinase A activity that is downstream of the ␤-adrenergic receptor (7) . Perturbed adrenergic response in Cav-1 Ϫ/Ϫ hearts has not yet been reported. In fact, another group using a dog model of heart failure hypothesized that a relative increase in the amount of Cav-3, but not Cav-1, would augment the NO synthase pathway response to ␤-adrenergic agonists as a result of compartmentalization of the pathway elements to plasma membrane agonist receptors, while at the same time inhibiting basal NO synthase activity since caveolin acts as a NO synthase inhibitor (10) . This is consistent with the findings in the present study which also illustrates that Cav-1 does not alter ␤-adrenergic response. Hearts perfused for 10 min showed significantly more MMP-2 gelatinolytic activity than hearts perfused for 90 min (*P Ͻ 0.0001), and Cav-1 Ϫ/Ϫ hearts perfused for 10 min showed more gelatinolytic activity than Cav-1 ϩ/ϩ hearts perfused for the same amount of time ( †P ϭ 0.0332). Age-related changes have also been observed in these Cav-1 Ϫ/Ϫ mouse hearts and may play a significant role in the similar biochemical results between the knockout and wild-type mouse strains. In this study, the mice were between 6 and 8 wk of age, which is younger than many studies that report changes in heart function and morphology (6, 13, 29) . Further confounding this issue is the fact that many studies that use Cav-1 Ϫ/Ϫ mouse hearts do not indicate the age at which these mice were used, which may further explain literature discrepancies regarding the heart function of these mice. This issue is of particular importance, since changes in the structure of these hearts is evident as early as 10 wk of age (13) . By 5 mo of age, hypertrophic changes are apparent in the Cav-1 Ϫ/Ϫ mice and functional changes are measureable by echocardiography (29) . We chose to use mice between 6 and 8 wk of age to elucidate whether the alterations in MMP-2 previously described (5) would lead to functional changes independent of the structural changes observed by others. Whether these changes occur subsequently as a result of the observed pulmonary hypertension, or concurrently, are not yet fully elucidated. It is also possible that the structural and functional changes observed in these hearts are a result of prolonged exposure to increased MMP-2 activity, particularly as it has been shown that MMP-2 can play a role in the mechanisms leading to hypertrophic changes (2, 8, 25) .
Following ischemia and reperfusion injury, MMP-2 was shown to cause degradation of important sarcomeric and cytoskeletal proteins (22, 23, 26, 27) . Also, a decrease in myocardial Cav-1 content has been observed following ischemia and reperfusion injury (1) . Both of these observations, as well as the fact that the caveolin scaffolding domain has been shown to inhibit MMP-2 activity (5), supports the hypothesis that Cav-1 may play a role in regulating the potentially destructive properties of this intracellular enzyme. The experimental design of this study may have obscured any potential changes observed in MMP-2 substrates. The administration of isoproterenol could lead to the activation of numerous protein kinases, including protein kinase A and protein kinase C, the latter of which has been shown to phosphorylate and diminish the activity of MMP-2 in vitro (20) . Though the data from this study do not indicate a role of Cav-1 regulation of MMP-2 during aerobic perfusion of young mouse hearts, this does not exclude a role of this protein during periods of more intense oxidative stress or later in life. Studies are currently underway to address this important issue. 
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